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Objective: Various techniques are available for radiotherapy of hepatocellular carcinoma,
including three-dimensional conformal radiotherapy, linac-based intensity-modulated radio-
therapy and helical tomotherapy. The purpose of this study was to determine the optimal
radiotherapy technique for hepatocellular carcinoma.
Methods: Between 2006 and 2007, 12 patients underwent helical tomotherapy for locally
advanced hepatocellular carcinoma. Helical tomotherapy computerized radiotherapy planning
was compared with the best computerized radiotherapy planning for three-dimensional con-
formal radiotherapy and linac-based intensity-modulated radiotherapy for the delivery of
60 Gy in 30 fractions. Tumor coverage was assessed by conformity index, radical dose hom-
ogeneity index and moderated dose homogeneity index. Computerized radiotherapy planning
was also compared according to the tumor location.
Results: Tumor coverage was shown to be significantly superior with helical tomotherapy as
assessed by conformity index and moderated dose homogeneity index (P ¼ 0.002 and 0.03,
respectively). Helical tomotherapy showed significantly lower irradiated liver volume at 40, 50
and 60 Gy (V40, V50 and V60, P ¼ 0.04, 0.03 and 0.01, respectively). On the contrary, the
dose–volume of three-dimensional conformal radiotherapy at V20 was significantly smaller
than those of linac-based intensity-modulated radiotherapy and helical tomotherapy in the
remaining liver (P ¼ 0.03). Linac-based intensity-modulated radiotherapy showed better
sparing of the stomach compared with helical tomotherapy in the case of separated lesions in
both lobes (12.3 vs. 24.6 Gy). Helical tomotherapy showed the high dose–volume exposure
to the left kidney due to helical delivery in the right lobe lesion.
Conclusions: Helical tomotherapy achieved the best tumor coverage of the remaining
normal liver. However, helical tomotherapy showed much exposure to the remaining liver at
the lower dose region and left kidney.
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INTRODUCTION
Radiotherapy (RT) of hepatocellular carcinoma (HCC) has
long been overlooked for fear that radiation might induce
fatal hepatic toxicity at doses lower than therapeutic doses
(1,2). However, recent developments in RT technology have
overcome this limitation by delivering focused, high-dose,
partial liver RT (3–8). In fact, the use of RT in treating
HCC is rapidly increasing, as evidenced by the increasing
number of publications in PubMed, from 11 in 1990 to 77
in 2008.
Various RT modes are available from three-dimensional
conformal RT (3D-CRT) to more sophisticated techniques
including intensity-modulated RT (IMRT) and image-guided
RT (IGRT). Of these techniques, 3D-CRT is most com-
monly used for HCC (9,10). Helical tomotherapy (HT) is a
sort of fusion technology that combines IMRT and IGRT
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(11,12). Because of its 3608 beam arrangement and helical
delivery of radiation, HT computerized RT planning
(CRTP) may provide equal or better tumor coverage and pro-
tection of healthy tissues compared with linac-based
step-and-shoot IMRT (L-IMRT) or 3D-CRT CRTP for
various tumors (13–15). HT also has wider applications,
ranging from total marrow irradiation to radiosurgery
(16,17); however, the application of HT in HCC has been
very limited (18,19).
The goal of RT for HCC is to maximize therapeutic
effects by escalating the radiation dose while simultaneously
sparing the adjacent normal organs. The liver is one of the
largest organs of the body; its asymmetric shape has been
divided by Couinaud (20) into eight independent segments.
Tumor location should be taken into account when perform-
ing local RT of HCC to minimize radiation complications
not only of the liver but also of adjacent organs.
At Yonsei University, HT has been used to treat HCC since
2006. Although HT is known to provide better dose coverage
for tumors in general, the effectiveness of HT for liver tumors
speciﬁcally is not known. Therefore, we evaluated dose con-
formity of 3D-CRT, L-IMRT and HT in patients with locally
advanced HCC. The purpose of this study was to determine
the optimal RT for locally advanced HCC.
PATIENTS AND METHODS
Between August 2006 and December 2007, 12 patients
underwent HT for locally advanced HCC. The ‘locally
advanced hepatocellular carcinoma’ was deﬁned as the
disease not amenable to surgical resection or immediate
liver transplantation, and the disease should be locally
advanced as deﬁned by BCLC (B) intermediate stage or
BCLC (C) advanced stage without extrahepatic spread
except regional lymph node involvement (21). A total of six
patients (50%) were treated with additional therapy before
receiving RT including: transcatheter arterial chemoemboli-
zation (TACE), transcatheter arterial chemoinfusion or
systemic chemotherapy, and local therapy such as radio-
frequency ablation and surgery. In these patients, RT was
chosen as a salvage modality aim. For locally advanced
HCC such as large tumor or portal vein thrombosis, concur-
rent chemoradiotherapy with intra-arterial chemoinfusion
was done as a deﬁnitive aim.
Their HT CRTP was compared with the best CRTPs for
3D-CRT and L-IMRT. HT CRTP was performed with
Tomotherapy Hi-Art Systemw (TomoTherapy, USA),
L-IMRT CRTP was performed with Corvusw (Nomos,
USA) and 3D-CRT CRTP was performed with the Pinnacle
planning system (Philips, USA). The L-IMRT and HT plan-
ning systems use different dose calculation algorithms;
Corvusw uses a ﬁnite-size pencil beam algorithm and calcu-
lations were based on the work of Nizin (22), whereas HT
uses a superposition convolution algorithm (23). We used
heterogeneity correction for both L-IMRT and HT CRTP.
For planning computed tomography (CT) scans, patients
were positioned supine with their arms above the head. The
BodyFIXw vacuum immobilization system (Medical
Intelligence Corp., Germany) was used to reduce the plan-
ning target volume (PTV) and minimize patient’s respiratory
motion. Planning CT was performed with a helical CT simu-
lator (Marconi, Picker PQ 5000, USA) with 5 mm slice
thickness. To verify craniocaudal motion, we also checked
diaphragm movement by ﬂuoroscopic imaging during the
simulation. The clinical target volume was expanded accord-
ing to the degree of diaphragm movement to create the PTV,
which was prescribed as 60 Gy in 30 fractions. Target
volume receiving at least 95% of the prescribed dose should
reach values of 100%.
To determine which RT mode provides the best conformal
coverage (conformity), two parameters—conformity index
(CI) and homogeneity index—were analyzed. CI is deﬁned
as the ratio of the treated volume (TV) to the PTV (24)
CI ¼ TV
PTV
Radical dose homogeneity index (rDHI) and moderate DHI
(mDHI) were deﬁned as the ratio of Dmin (minimum dose
within target volume) to Dmax (maximum dose within target
volume), and the ratio of D95% (dose to 95% of target






The mean dose, V20, V30, V40, V50 and V60 were com-
pared for the remaining normal liver and stomach. We
selected three patients with the different locations of the
liver lesion. CRTPs were also compared according to the
tumor location; three different tumor locations were ana-
lyzed, which correspond to Couinaud’s liver segment classi-
ﬁcation as follows: right lobe lesions, lesions in both lobes
and left lobe lesions; right lobe lesions at S5–8 and S5–6,
right lobe mass at S5–6, separated lesions at S4 and S5–6,
and left lobe lesion. For IMRT CRTP, a non-coplanar tech-
nique was also allowed.
RESULTS
COVERAGE OF TARGET VOLUME ALONG THE TUMOR CONTOURS
Patient characteristics including stage, tumor location,
volume of target tissue and adjacent normal organs (organs
at risk) are displayed in Table 1. The patients staged accord-
ing to the modiﬁed UICC staging classiﬁcation. Three of
them showed portal vein thrombosis. The target volume cov-
erage and dosimetric data of 3D-CRT, L-IMRT and HT





















CRTP for 12 patients are shown in Table 2. The CI and
mDHI were signiﬁcantly improved with HT CRTP compared
with the 3D-CRT and L-IMRT CRTPs (P ¼ 0.002 and 0.03,
respectively). rDHI of HT CRTP also improved, but did not
show statistically signiﬁcant difference.
SPARING OF ADJACENT NORMAL ORGANS
The dosimetric data of 3D-CRT, L-IMRT and HT for the
remaining normal liver, stomach and small bowel are shown
in Table 3. The high-dose region, the volume fraction of the
Table 1. Patient characteristics
Case no. Age/sex Stage Child–Pugh class GTV (cc)
Organs at risk
Tumor locationRemaining liver (cc) Stomach (cc) Small bowel (cc)
1 48/M T3N0 A 483.4 1760.2 565.9 452.4 S4
2 62/F T4N1 B 228.2 1110.9 160.5 416.2 Lt. lobe with L/N metastasis
3 64/M T4N0 A 1280.4 942.7 248.9 972.1 S4, PVT
4 79/M T4N0 A 396.7 1696.6 206.6 754.9 Rt. lobe and S4 (separated lesions)
5 55/M T3N0 A 297.9 823.7 141.1 654.9 S4
6 53/M T4N0 A 307.1 894.9 232.6 451.8 Rt. lobe (S6), PVT
7 55/M T3N0 A 203.1 1331.8 209.0 884.3 S2 and S5 (separated lesions)
8 59/M T3N0 A 425.4 1042.3 429.9 150.2 Lt. lobe
9 56/M T4N0 A 372.2 1165.4 232.7 232.7 Rt. lobe (S5 and 6)
10 48/M T4N0 A 2079.9 917.0 138.0 856.8 Rt. lobe (S5–8), PVT
11 64/M T4N0 A 490.7 1775.2 359.5 302.1 Lt. lobe
12 52/M T3N0 A 177.9 1536.6 141.0 408.1 Rt. lobe (S5)
GTV, gross tumor volume; Lt., left; L/N, lymph node; PVT, portal vein thrombosis; Rt., right.




3D-CRT L-IMRT HT 3D-CRT L-IMRT HT 3D-CRT L-IMRT HT
1 2.32 1.05 1.03 0.79 0.80 0.84 0.90 0.91 0.93
2 2.15 1.12 1.04 0.83 0.84 0.87 0.90 0.91 0.94
3 1.65 1.05 1.04 0.45 0.39 0.69 0.91 0.86 0.89
4 1.83 1.24 1.08 0.81 0.82 0.83 0.92 0.90 0.91
5 1.59 1.12 1.04 0.82 0.83 0.85 0.90 0.91 0.94
6 1.72 1.18 1.07 0.82 0.83 0.83 0.94 0.91 0.92
7 5.86 1.12 1.06 0.76 0.82 0.84 0.84 0.90 0.93
8 2.05 1.11 1.04 0.81 0.82 0.84 0.88 0.90 0.93
9 1.61 1.38 1.19 0.67 0.82 0.83 0.93 0.94 0.98
10 2.11 1.99 1.10 0.77 0.81 0.82 0.90 0.93 0.95
11 1.34 1.19 1.11 0.80 0.82 0.83 0.95 0.97 0.98
12 1.41 1.25 1.12 0.77 0.78 0.80 0.89 0.92 0.93
Mean 2.14+1.16 1.23+0.25 1.07+0.05 0.75+0.11 0.78+0.12 0.82+0.05 0.91+0.03 0.91+0.03 0.93+0.02
P value 0.002 0.28 0.03
CI, conformity index; rDHI, radical dose homogeneity index; mDHI, moderate dose homogeneity index; 3D-CRT, three-dimensional conformal radiotherapy;
L-IMRT, linac-based intensity modulated radiotherapy; HT, helical tomotherapy.





















remaining liver receiving more than 40 Gy (V40) in HT
CRTP, was smaller compared with the other RT techniques.
For the low-dose region (V20), the volume fraction of the
remaining liver of 3D-CRT was signiﬁcantly smaller than
those of L-IMRT and HT (P ¼ 0.03). Table 3 shows a sig-
niﬁcant reduction in irradiated fractional volume of the
remaining normal liver at V40 (P ¼ 0.04), V50 (P ¼ 0.03)
and V60 (P ¼ 0.01) by HT CRTP. HT CRTP also reduced
the volume fraction of the stomach receiving more than
40 Gy (54.5 and 38.3% compared with 3D-CRT and
L-IMRT, respectively); however, this reduction was not sig-
niﬁcant (Table 3). The V50 and V60 of the stomach were
also decreased with HT CRTP, but this was not signiﬁcant.
The volume of high-dose area (V40, V50 and V60) of the
small bowel was also decreased with HT CRTP, but this was
not signiﬁcant. The mean doses for the stomach, small
bowel and remaining normal liver using L-IMRT and HT
CRTP were higher than the mean doses using 3D-CRT
CRTP.
Radiation dosimetric displays for 3D-CRT, L-IMRT and
HT CRTP are shown in Fig. 1 according to the tumor
location. The V50 of the remaining normal liver was
decreased by L-IMRT and HT CRTP for the right lobe
lesion; however, 3D-CRT CRTP achieved better sparing of
the adjacent organs in the low-dose region (Fig. 2). The
mean doses for the remaining normal liver with 3D-CRT
and L-IMRT (14.2 and 15.7 Gy, respectively) were lower
compared with HT (19.3 Gy). For separated lesions in both
lobes, the mean doses for the remaining normal liver were
not signiﬁcantly different among the RT techniques (25.8–
27.63 Gy). For the left lobe lesion, 3D-CRT and L-IMRT
CRTP achieved lower mean doses for the remaining normal
liver (14.9 and 15.9 Gy, respectively) compared with HT
(22.3 Gy). However, a dose reduction in the stomach V50
(3.4%) was observed with HT CRTP compared with
Table 3. Dosimetric data of 3D-CRT, L-IMRT and HT for the remaining
normal liver and stomach
Organs at risk 3D-CRT L-IMRT HT P value
Remaining liver
Mean dose (Gy) 20.9+6.8 22.6+11.4 24.9+7.6 0.01
V20 (%) 42.04+14.35 71.07+23.44 65.78+22.4 0.03
V30 (%) 30.11+11.09 50.01+18.02 39.61+17.95 0.07
V40 (%) 17.8+10.3 29.4+12.1 17.8+13.8 0.04
V50 (%) 11.1+6.7 15.3+7.5 7.6+6.1 0.03
V60 (%) 3.9+3.2 2.1+1.5 0.4+0.3 0.01
Stomach
Mean dose (Gy) 16.1+10.4 22.6+5.7 21.3+6.3 0.11
V40 (%) 10.1+17.3 7.5+11.3 4.6+11.0 0.62
V50 (%) 6.8+13.4 2.6+6.1 2.0+6.0 0.39
V60 (%) 2.7+6.0 0.4+1.1 0.5+1.6 0.24
Small bowel
Mean dose (Gy) 10.14+6.9 14.74+5.67 14.38+4.71 0.12
V40 (%) 6.49+8.83 5.4+8.33 4.59+1.32 0.67
V50 (%) 3.39+4.59 2.53+3.83 1.54+1.66 0.46
V60 (%) 0.47+0.81 0.22+0.59 0.06+0.17 0.23
Figure 1. Axial isodose distributions of three-dimensional conformal RT (3D-CRT), linac-based intensity-modulated RT (L-IMRT) and helical tomotherapy
(HT). (A) Isodose distributions of 3D-CRT, L-IMRT and HT for the right lobe lesion. (B) Isodose distributions of 3D-CRT, L-IMRT and HT for the left lobe
lesion. (C) Isodose distributions of 3D-CRT, L-IMRT and HT for separated lesions at both. Color coding for the isodose color washes ranges from 20 Gy
color washes (light blue) to 66 Gy color washes (yellow).





















3D-CRT and L-IMRT (5.9 and 5.8%, respectively) in the
high-dose region.
Dose–volume histograms (DVH) of the stomach are dis-
played for 3D-CRT, L-IMRT and HT in Fig. 2. For the sep-
arated lesion in both lobes, the mean stomach doses for
3D-CRT, L-IMRT and HT were 20.9, 12.3 and 24.6 Gy,
respectively. For the left lobe lesion, the mean stomach
doses for 3D-CRT, L-IMRT and HT were 41.6, 30.6 and
37.6 Gy, respectively. The V50 values for 3D-CRT, L-IMRT
and HT were 48.1, 16.9 and 21.0%, respectively. A
conformal treatment plan for L-IMRT was successfully gen-
erated with decreased mean stomach dose in cases of the
separated lesion in both lobes and left lobe lesion (12.3 and
30.6 Gy, respectively). The DVH of the right kidney and left
kidney are also displayed in Fig. 2. In the right lobe lesion
and separated lesions at both lobes, L-IMRT resulted in less
exposed to the right kidney and left kidney than 3D-CRT
and tomotherapy, respectively. HT plan showed the high
dose–volume exposure to the left kidney due to helical
delivery in the right lobe lesion.
Figure 2. Dose–volume histograms of the remaining liver, stomach, right kidney and left kidney according to the tumor location; (A) right lobe lesion, (B)
left lobe lesion and (C) separated lesions at both lobes.






















For patients with locally advanced HCC, several factors
should be considered while selecting appropriate RT tech-
nique. Although 3D-CRT has been the most commonly used
technique for HCC (9,10), analysis of dosimetric plans for
3D-CRT, L-IMRT and HT is needed to compare target cov-
erage and organ sparing. HT delivers its dose from 3608 and
may produce detrimental effects on non-tumor liver tissue.
Cheng et al. (26) compared dose–volume data between
3D-CRT and L-IMRT for patients with HCC. They found
that L-IMRT achieved a large dose reduction in the spinal
cord and spared the kidney and stomach. L-IMRT exerted
diverse dosimetric effects on the liver, signiﬁcantly reducing
the normal tissue complication probability (P ¼ 0.009), but
signiﬁcantly increasing the mean dose compared with
3D-CRT (P ¼ 0.009). Some studies have reported improved
sparing of adjacent normal organs when using HT in various
tumors, and HT offers increased dose conformity to the
tumor and reduces doses received by sensitive structures
(13,14). In the present study, we found that HT decreased
high-dose radiation to certain critical structures like the
stomach, whereas the mean hepatic dose was increased.
Proton therapy is a type of positively charged particle
therapy with a unique dose distribution which makes them
suitable for the treatment of deep tumors surrounded by
normal structures. Several authors reviewed clinical out-
comes of the HCC patients treated with proton beam therapy
(PBT) (27–29). Recently, Kawashima et al. (30) reported
Phase II study proton therapy for HCC. Thirty patients were
enrolled between May 1999 and February 2003. After a
median follow-up period of 31 months (16–54 months),
only one patient experienced recurrence of the primary
tumor, and the 2-year actuarial local progression-free rate
was 96%. The actuarial overall survival rate at 2 years was
66% (48–84%). Li et al. (31) conducted a comparative dose
distribution study of treatment planning between PBT,
3D-CRT and IMRT in the treatment of HCC, so as to assess
the potential advantages of PBT. DVH were compared
between PBT and 3D-CRT or IMRT planning at a total dose
of 66 and 86 Gy in Stage I patients (n ¼ 10, diameter 
5 cm), 60 and 72 Gy in Stage IIA patients (n ¼ 12,
diameter ¼ 5.1–10 cm). Compared with 3D-CRT and IMRT,
PBT signiﬁcantly reduced the Dmean, V10, V20 and V30 in
all patients. PBT reduced the dose to the right kidney and
stomach signiﬁcantly. No signiﬁcant difference was observed
respect to the dose to spinal cord. Further study of dose dis-
tribution in the treatment of advanced HCC might be necess-
ary, because this study compared only Stage I and IIA
disease.
The liver is one of the largest organs of the body; its tri-
angular shape renders different adjacent organs such as the
duodenum, colon, small bowels and kidney vulnerable
depending on the liver segment involved (20). Park et al.
reported that the incidence of acute morbidity was signiﬁ-
cantly affected depending on the lobe that was irradiated.
Among the 47 patients who underwent 3D-CRT on the right
lobe only, 26 patients (55.3%) developed acute morbidity,
including nausea and vomiting. In contrast, 11 of 12 patients
(91.7%) irradiated on the left lobe developed acute morbidity
(8). In our previous study of HCC patients who were treated
with 3D-CRT combined with transarterial chemoemboliza-
tion (TACE), seven patients (14%) developed a gastroduode-
nal side effect, six patients (12%) developed
radiation-induced liver disease and one patient (2%) devel-
oped subacute colitis after irradiation of a tumor in segment
5 of the liver (9).
Depending on the tumor location, non-coplanar L-IMRT
may improve stomach sparing in patients with left lobe lesions
and separated lesions in both lobes. However, non-coplanar
L-IMRT generally takes more time because automatic ﬁeld
sequencing is not possible and extra time is required for couch
moving. In addition, HT effects may vary depending on the
tumor location. Patients with a large centrally located tumor
may have more normal liver tissue surrounding the target,
which inevitably results in more liver volume receiving radi-
ation and an increased mean hepatic dose. With delivery by
HT, improved dose conformity to the tumor targets is achieved
with the price of increased mean hepatic dose.
In the case of HCC patients with left lobe lesions, we can
protect the right lobe with a directional beam blocking tech-
nique as shown in Fig. 3. Directional blocking allows a
beam to pass through a given structure only after passing
through the PTV, such that the structure receives the exit
dose but not the entrance dose (32). HT CRTP with direc-
tional beam blocking for the right lobe produced a mean
dose for the remaining liver (16.2 Gy) that was similar to
that produced by 3D-CRT and L-IMRT (14.9 and 15.9 Gy,
respectively) and improved the remaining liver dose com-
pared with conventional HT (22.3 Gy).
Finally, the liver moves with respiration, so tumor move-
ment due to respiration should be considered when applying
RT. A limitation of the present study is the interplay effect
between the multileaf collimator and tumor motion in HT. A
recent study using motion phantoms measured the interplay
of parameters between HT deliver and target motion and
concluded that HT delivery was not affected by tumor
motion (33). In our previous study, the interfractional shift
pattern was assessed according to the tumor location (34).
We suggested that a more sophisticated approach is required
in the free-breathing mode when the left lobe of the liver is
irradiated to avoid stomach toxicity. It may also important to
reduce motion or gating during HT to reduce the target
margins. Therefore, we use the BodyFIXw vacuum immo-
bilization (Medical Intelligence Corp., Germany) to decrease
the PTV and minimize patient’s respiratory motion.
Because complete necrosis is seldom observed with mono-
therapy such as 3D-CRT, multimodality therapy may be
useful in patients with locally advanced HCC (7,9). We pre-
viously reported that concurrent chemoradiation therapy fol-
lowed by hepatic arterial infusion chemotherapy for
advanced HCC with portal vein thrombosis substantially





















improved the response rate and median survival time (35).
McIntosh et al. (18) assessed the initial clinical experience
with HT plus capecitabine in patients with large HCC
lesions and found acceptable toxicity with promising local
control. Therefore, prospective trials are needed to evaluate
concurrent chemoradiation therapy with radiation dose esca-
lation by HT for locally advanced HCC.
CONCLUSIONS
Compared with L-IMRT and 3D-CRT, HT provided the best
tumor coverage of the remaining liver. However, HT showed
much exposure to the remaining liver at the lower dose
region and left kidney. For patients with separated lesions in
both lobes, L-IMRT offered better sparing of the stomach.
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